301 Binney Street
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma.
295 articles with Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present clinical data for IW-3718, and both clinical and non-clinical data for linaclotide during Digestive Disease Week (DDW) being held in San Diego, CA, May 18 through May 21, 2019.
Ironwood Pharmaceuticals, Inc. will present a corporate update at the 2019 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 14, 2019 at 8:00 a.m. Pacific Time at The Encore Hotel in Las Vegas.
Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance
Ironwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2019 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 2, 2019.
Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
Ironwood Pharmaceuticals, Inc. announced an adjustment to the conversion rate applicable to its existing 2.25% Convertible Senior Notes due 2022, effective April 15, 2019.
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion Therapeutics, Inc. (Cyclerion).
Today, Cyclerion has been launched on the second floor of a 200,000-square-foot , 3-story space on Binney Street, in Cambridge.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC).
Ironwood Pharmaceuticals, Inc. will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 14, 2019 at 2:35 p.m. Eastern Time at The Loews Miami Beach Hotel in Miami.
With Boston and the surrounding area being one of the centers of the pharmaceutical world, it should come as no surprise that some of the top-selling medications are based in the Bay State.
Ironwood Pharmaceuticals, Inc. will present a corporate update at the 39th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.m. Eastern Time at The Boston Marriott Copley Place in Boston.
Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering
Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases
Ironwood Pharmaceuticals, Inc. will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2018 results and recent business activities.
Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
Important step toward launching two independent, publicly-traded companies
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2018 investor update conference call and webcast at 8:30 a.m.
1/25/2019Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
Board members bring diverse experience tailored to the distinct opportunities and strategies of each new company
Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials
Ironwood Pharmaceuticals (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders.
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C
Ironwood anticipates that it will launch the drug with its partner in China, AstraZeneca, in the second half of 2019.